Catherine A. Sohn's Insider Trades & SAST Disclosures
Catherine A. Sohn's most recent trade in Altimmune Inc was a trade of 18,600 Stock Options (option to buy) done . Disclosure was reported to the exchange on Feb. 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Catherine A. Sohn.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 18,600 | 18,600 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Angell Sohn Catherine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Jazz Pharmaceuticals plc | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 3,075 | 16,109 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Catherine Angell Sohn | Director | Sale of securities on an exchange or to another person at price $ 138.16 per share. | 11 Aug 2023 | 1,241 | 14,868 (0%) | 0% | 138.2 | 171,455 | Ordinary Shares |
| Altimmune Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2023 | 47,000 | 47,000 | - | - | Stock Options (option to buy) | |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 2,561 | 14,123 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Sale of securities on an exchange or to another person at price $ 152.32 per share. | 05 Aug 2022 | 1,089 | 13,034 (0%) | 0% | 152.3 | 165,880 | Ordinary Shares |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 9.50 per share. | 04 Jun 2022 | 7,059 | 54,069 (0%) | 0% | 9.5 | 67,061 | Common Stock |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2022 | 7,059 | 0 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 9,474 | 9,474 | - | - | Restricted Stock Unit | |
| Axcella Health Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Sale of securities on an exchange or to another person at price $ 147.96 per share. | 06 Aug 2021 | 1,306 | 11,562 (0%) | 0% | 148.0 | 193,236 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 2,246 | 12,868 (0%) | 0% | 0 | Ordinary Shares | |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 7,059 | 7,059 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 11.64 per share. | 01 Jun 2021 | 8,303 | 47,010 (0%) | 0% | 11.6 | 96,647 | Common Stock |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 8,303 | 0 | - | - | Restricted Stock Unit | |
| Axcella Health Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 8,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Sale of securities on an exchange or to another person at price $ 152.00 per share. | 04 Nov 2020 | 8,000 | 10,622 (0%) | 0% | 152 | 1,216,000 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.83 per share. | 04 Nov 2020 | 8,000 | 18,622 (0%) | 0% | 46.8 | 374,640 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.76 per share. | 04 Nov 2020 | 4,500 | 15,122 (0%) | 0% | 81.8 | 367,920 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Sale of securities on an exchange or to another person at price $ 156.00 per share. | 04 Nov 2020 | 4,500 | 10,622 (0%) | 0% | 156 | 702,000 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 4,500 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,200 | 0 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 10.36 per share. | 15 Oct 2020 | 2,200 | 38,707 (0%) | 0% | 10.4 | 22,792 | Common Stock |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 6,765 | 6,765 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 2,705 | 11,553 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Catherine A. Sohn | Director | Sale of securities on an exchange or to another person at price $ 125.87 per share. | 06 Aug 2020 | 931 | 10,622 (0%) | 0% | 125.9 | 117,186 | Ordinary Shares |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 8,303 | 8,303 | - | - | Right to Buy Restricted Stock Unit (RSU) | |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 10.99 per share. | 28 May 2020 | 6,000 | 36,507 (0%) | 0% | 11.0 | 65,940 | Common Stock |
| Lifecore Biomedical Inc | Catherine A. Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Axcella Health Inc | Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges